Targeting TACE-dependent EGFR ligand shedding in breast cancer

Journal of Clinical Investigation

Volumn 117, Issue 2, 2007, Pages 337-345

  Kenny, Paraic A ^a   Bissell, Mina J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL LINE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MOBILIZATION; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE;

ADAM PROTEINS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SUBSTRATE SPECIFICITY; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 33846817495     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29518     Document Type: Article

References (42)

1. Bissell, M.J., et al. 1999. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res. 59(7 Suppl.):1757s-1763s; discussion 1763s-1764s.
2. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
3. Wiesen, J.F., Young, P., Werb, Z., and Cunha, G.R. 1999. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development. 126:335-344.
4. Luetteke, N.C., et al. 1999. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development. 126:2739-2750.
5. Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 3:11-22.
6. Briand, P., Petersen, O.W., and Van Deurs, B. 1987. A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell. Dev. Biol. 23:181-188.
7. Petersen, O.W., Ronnov-Jessen, L., Howlett, A.R., and Bissell, M.J. 1992. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 89:9064-9068.
8. Briand, P., Nielsen, K.V., Madsen, M.W., and Petersen, O.W. 1996. Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Res. 56:2039-2044.
9. Weaver, V.M., et al. 1997. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137:231-245.
10. Wang, F., et al. 1998. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc. Natl. Acad. Sci. U. S. A. 95:14821-14826.
11. Borrell-Pages, M., Rojo, F., Albanell, J., Baselga, J., and Arribas, J. 2003. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J. 22:1114-1124.
12. Gschwind, A., Hart, S., Fischer, O.M., and Ullrich, A. 2003. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. 22:2411-2421.
13. Sahin, U., et al. 2004. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 164:769-779.
14. Zhou, B.B., et al. 2006. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 10:39-50.
15. van de Vijver, M.J., et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009.
16. Wang, F., et al. 2002. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J. Natl. Cancer Inst. 94:1494-1503.
17. Sternlicht, M.D., et al. 2005. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development. 132:3923-3933.
18. Moss, M.L., et al. 1997. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 385:733-736.
19. Black, R.A., et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 385:729-733.
20. Peschon, J.J., et al. 1998. An essential role for ectodomain shedding in mammalian development. Science. 282:1281-1284.
21. Buxbaum, J.D., et al. 1998. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273:27765- 27767.
22. Franzke, C.W., et al. 2002. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J. 21:5026-5035.
23. Zhang, Y., Jiang, J., Black, R.A., Baumann, G., and Frank, S.J. 2000. Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology. 141:4342-4348.
24. Diaz-Rodriguez, E., Montero, J.C., Esparis-Ogando, A., Yuste, L., and Pandiella, A. 2002. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol. Biol. Cell. 13:2031-2044.
25. Rio, C., Buxbaum, J.D., Peschon, J.J., and Corfas, G. 2000. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J. Biol. Chem. 275:10379-10387.
26. Bergmeier, W., et al. 2004. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ. Res. 95:677-683.
27. Perou, C.M., et al. 2000. Molecular portraits of human breast tumours. Nature. 406:747-752.
28. Shoyab, M., McDonald, V.L., Bradley, J.G., and Todaro, G.J. 1988. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc. Natl. Acad. Sci. U. S. A. 85:6528-6532.
29. Martinez-Lacaci, I., et al. 1995. Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. Endocrinology. 136:3983-3992.
30. Schafer, B., Marg, B., Gschwind, A., and Ullrich, A. 2004. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J. Biol. Chem. 279:47929-47938.
31. Giaccone, G., et al. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J. Clin. Oncol. 22:777-784.
32. Herbst, R.S., et al. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 22:785-794.
33. Moore, M.J., et al. 2005. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. In American Society of Clinical Oncology Gastrointestinal Cancers Symposium. January 27-29. Hollywood, Florida, USA. Abstract 77.
34. Shepherd, F.A., et al. 2005. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353:123-132.
35. Lynch, T.J., et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-2139.
36. Paez, J.G., et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497-1500.
37. Tsao, M.S., et al. 2005. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353:133-144.
38. Coussens, L.M., Fingleton, B., and Matrisian, L.M. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2387-2392.
39. Egeblad, M., and Werb, Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2:161-174.
40. Beck, G., et al. 2002. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3- butenyl]-2′-isobutyl-2′-(meth anesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J. Pharmacol. Exp. Ther. 302:390-396.
41. Zhang, Y., et al. 2004. Characterization of (2R, 3S)-2-({[4-(2- butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Int. Immunopharmacol. 4:1845-1857.
42. Garton, K.J., Ferri, N., and Raines, E.W. 2002. Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors. Biotechniques. 32:830, 832, 834 passim.